Editas Medicine
EDIT
208 hedge funds and large institutions have $128M invested in Editas Medicine in 2026 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 50 reducing their positions, and 24 closing their positions.
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
28% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $855K
24% more capital invested
Capital invested by funds: $102M → $128M (+$25M)
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
6% more funds holding
Funds holding: 197 → 208 (+11)
1.79% more ownership
Funds ownership: 51.17% → 52.96% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.08M |
| 2 |
JP Morgan Chase
New York
|
+$2.46M |
| 3 |
Renaissance Technologies
New York
|
+$1.97M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.77M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.21M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.34M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$879K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$688K |
EDIT Hedge Fund Activity: Q1 2026 in Review
208 of the 8,177 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2026, worth a combined $128M — up 24% from $102M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new EDIT positions and 24 closed out — a net gain of 14 holders — while 58 added to existing stakes and 50 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $4.08M. The largest seller was Jane Street, cutting an estimated $2.21M.
- 208 institutional investors held Editas Medicine (EDIT) as of Q1 2026, up from 197 in Q4 2025.
- Funds reported $128M of Editas Medicine stock for Q1 2026, up 24% quarter-over-quarter.
- 38 funds opened new Editas Medicine positions in Q1 2026 and 24 closed out, a net change of +14 holders.
- The largest Editas Medicine buyer in Q1 2026 was Opaleye Management, an estimated $4.08M added.
- The largest Editas Medicine seller in Q1 2026 was Jane Street, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2026.